Background: Radiomics shows promise in characterizing glioblastoma, but its added value over clinical and molecular predictors has yet to be proven. This study assessed the added value of conventional radiomics (CR) and deep learning (DL) MRI radiomics for glioblastoma prognosis (<= 6 vs > 6 months survival) on a large multi-center dataset. Methods: After patient selection, our curated dataset gathers 1152 glioblastoma (WHO 2016) patients from five Swiss centers and one public source. It included clinical (age, gender), molecular (MGMT, IDH), and baseline MRI data (T1, T1 contrast, FLAIR, T2) with tumor regions. CR and DL models were developed using standard methods and evaluated on internal and external cohorts. Sub-analyses assessed models with different feature sets (imaging-only, clinical/molecular-only, combined-features) and patient subsets (S-1: all patients, S-2: with molecular data, S-3: IDH wildtype). Results: The best performance was observed in the full cohort (S-1). In external validation, the combined-feature CR model achieved an AUC of 0.75, slightly, but significantly outperforming clinical-only (0.74) and imaging-only (0.68) models. DL models showed similar trends, though without statistical significance. In S-2 and S-3, combined models did not outperform clinical-only models. Exploratory analysis of CR models for overall survival prediction suggested greater relevance of imaging data: across all subsets, combined-feature models significantly outperformed clinical-only models, though with a modest advantage of 2-4 C-index points. Conclusions: While confirming the predictive value of anatomical MRI sequences for glioblastoma prognosis, this multi-center study found standard CR and DL radiomics approaches offer minimal added value over demographic predictors such as age and gender.

Background: This research aims to improve glioblastoma survival prediction by integrating MR images, clinical and molecular-pathologic data in a transformer-based deep learning model, addressing data heterogeneity and performance generalizability. Method: We propose and evaluate a transformer-based non-linear and non-proportional survival prediction model. The model employs self-supervised learning techniques to effectively encode the high-dimensional MRI input for integration with non-imaging data using cross-attention. To demonstrate model generalizability, the model is assessed with the time-dependent concordance index (Cdt) in two training setups using three independent public test sets: UPenn-GBM, UCSF-PDGM, and RHUH-GBM, each comprising 378, 366, and 36 cases, respectively. Results: The proposed transformer model achieved promising performance for imaging as well as non-imaging data, effectively integrating both modalities for enhanced performance (UPenn-GBM test-set, imaging Cdt 0.645, multimodal Cdt 0.707) while outperforming state-of-the-art late-fusion 3D-CNN-based models. Consistent performance was observed across the three independent multicenter test sets with Cdt values of 0.707 (UPenn-GBM, internal test set), 0.672 (UCSF-PDGM, first external test set) and 0.618 (RHUH-GBM, second external test set). The model achieved significant discrimination between patients with favorable and unfavorable survival for all three datasets (logrank p 1.9\times{10}^{-8}, 9.7\times{10}^{-3}, and 1.2\times{10}^{-2}). Conclusions: The proposed transformer-based survival prediction model integrates complementary information from diverse input modalities, contributing to improved glioblastoma survival prediction compared to state-of-the-art methods. Consistent performance was observed across institutions supporting model generalizability.

Objective: To report imaging protocol and scheduling variance in routine care of glioblastoma patients in order to demonstrate challenges of integrating deep-learning models in glioblastoma care pathways. Additionally, to understand the most common imaging studies and image contrasts to inform the development of potentially robust deep-learning models. Methods: MR imaging data were analysed from a random sample of five patients from the prospective cohort across five participating sites of the ZGBM consortium. Reported clinical and treatment data alongside DICOM header information were analysed to understand treatment pathway imaging schedules. Results: All sites perform all structural imaging at every stage in the pathway except for the presurgical study, where in some sites only contrast-enhanced T1-weighted imaging is performed. Diffusion MRI is the most common non-structural imaging type, performed at every site. Conclusion: The imaging protocol and scheduling varies across the UK, making it challenging to develop machine-learning models that could perform robustly at other centres. Structural imaging is performed most consistently across all centres. Advances in knowledge: Successful translation of deep-learning models will likely be based on structural post-treatment imaging unless there is significant effort made to standardise non-structural or peri-operative imaging protocols and schedules.

Glioblastomas (GBMs) are highly aggressive tumors. A common clinical challenge after standard of care treatment is differentiating tumor progression from treatment-related changes, also known as pseudoprogression (PsP). Usually, PsP resolves or stabilizes without further treatment or a course of steroids, whereas true progression (TP) requires more aggressive management. Differentiating PsP from TP will affect the patient's outcome. This study investigated using deep learning to distinguish PsP MRI features from progressive disease.

Patients with glioblastoma, a malignant tumor in the brain or spinal cord, typically live no more than five years after receiving their diagnosis. And those five years can be painful -- in an effort to minimize the tumor, doctors often prescribe a combination of radiation therapy and drugs that can cause debilitating side effects for patients. Now, researchers from MIT Media Lab have developed artificial intelligence (AI) that can determine the minimum drug doses needed to effectively shrink glioblastoma patients' tumors. They plan to present their research at Stanford University's 2018 Machine Learning for Healthcare conference. To create an AI that could determine the best dosing regimen for glioblastoma patients, the MIT researchers turned to a training technique known as reinforcement learning (RL). First, they created a testing group of 50 simulated glioblastoma patients based on a large dataset of those that had previously undergone treatment for their disease.

Differences in imaging equipment, procedures and protocols can dramatically affect the performance of deep machine learning when analyzing brain tumors, according to a new study in Medical Physics. Automatic brain tumor segmentation from MRI data using deep learning methodologies has gained steam in recent years. Convolutional neural networks (CNNs), a type of deep learning algorithm, are commonly used for segmentation of brain tumors, and provider organizations have recently begun sharing images to increase the data to work with. However, providers often use different imaging equipment, image acquisition parameters and contrast injection protocols, which could cause institutional bias; a CNN model trained on MRI data from one organization may stumble when tested on MRI data from another. The researchers, from the Radiology Department at Duke University School of Medicine, used MRI data of 22 glioblastoma patients from MD Anderson Cancer Center and 22 glioblastoma patients from Henry Ford Hospital to assess how CNN models worked with their own and each other's MRI data.